Adithya Chennamadhavuni
Overview
Explore the profile of Adithya Chennamadhavuni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ganiyani M, Addula M, Doddamani R, Chennamadhavuni A, Pustake M, Khosla A, et al.
J Adolesc Young Adult Oncol
. 2025 Feb;
PMID: 39960823
Cancer incidence (CI) and mortality vary significantly among countries and are impacted by numerous factors including the country's income and human development index (HDI). Cancer mortality (CM) in the adolescent...
2.
Chennamadhavuni A, Kasi P
Front Oncol
. 2022 Jul;
12:847299.
PMID: 35837097
For patients with metastatic wild-type refractory colorectal cancer, the question of anti-EGFR therapy rechallenge often comes up after initial use. However, not all patients derive benefit. It is now well...
3.
Chennamadhavuni A, Abushahin L, Jin N, Presley C, Manne A
Front Immunol
. 2022 May;
13:779691.
PMID: 35558065
Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic T-Lymphocyte Antigen 4 (CTLA4)...
4.
Sunkara T, Bandaru S, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A
Cureus
. 2022 Mar;
14(2):e22575.
PMID: 35228986
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival...
5.
Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
An J, Packiam V, Chennamadhavuni A, Richards J, Jain J, Mott S, et al.
Front Oncol
. 2022 Jan;
11:786307.
PMID: 35083144
Background: Non-clear cell renal cell carcinoma (ccRCC) includes histologically and molecularly distinct subtypes such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence ranging from 20% to 25%....
6.
An J, Yan M, Yu N, Chennamadhavuni A, Furqan M, Mott S, et al.
Transl Lung Cancer Res
. 2021 Sep;
10(8):3608-3615.
PMID: 34584860
Background: mutation ( ) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance...
7.
Vallatharasu Y, Chennamadhavuni A, Van Every M
Clin Med Res
. 2021 Apr;
19(2):72-81.
PMID: 33789953
Non-Hodgkin lymphoma is the seventh most common cancer in the United States. It may involve any extranodal organ, although involvement of the genitourinary (GU) tract accounts for <5% of all...
8.
Swami U, Chennamadhavuni A, Borcherding N, Bossler A, Mott S, Garje R, et al.
Antibiotics (Basel)
. 2020 Oct;
9(11).
PMID: 33120998
Recently antibiotic exposure has been associated with worse outcomes in patients undergoing treatment with antibodies directed against programmed cell death protein-1 (PD-1). We reviewed data of 1264 patients enrolled at...
9.
Vikas P, Borcherding N, Chennamadhavuni A, Garje R
Front Oncol
. 2020 May;
10:570.
PMID: 32457830
Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has improved outcome for patients with cancer across multiple tumor types, including lung, melanoma,...
10.
Garje R, Chennamadhavuni A, Mott S, Chambers I, Gellhaus P, Zakharia Y, et al.
Clin Genitourin Cancer
. 2020 Jan;
18(2):e157-e166.
PMID: 31956009
Background: Androgen deprivation therapy (ADT) is the gold standard for metastatic prostate cancer, which can be achieved either by surgical or medical castration. In this study, we evaluated the trends...